Uteroglobin in the treatment of IGA mediated nephropathy

Details Uteroglobin in the treatment of IGA mediated nephropathy Uteroglobin in the treatment of IGA mediated nephropathy

2007-11-01

2011-12-27

Kim, Yunsoo (Department: 1644)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200

Reexamination Certificate

active

08084415

ABSTRACT:
Uteroglobin has been discovered to prevent IgA mediated diseases, such as IgA nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or improve the IgA mediated condition. Transgenic uteroglobin knockout animals, and animals in which uteroglobin-protein expression is reduced by antisense technology, also provide systems for studying IgA mediated diseases, and screening for appropriate treatments.

REFERENCES:
patent: 5696092 (1997-12-01), Patierno et al.
patent: 6255281 (2001-07-01), Pilon et al.
patent: 2002/0006640 (2002-01-01), Ni et al.
patent: WO 98/53846 (1998-12-01), None
patent: WO 01/32677 (2001-05-01), None
Attwood, Science, 2000, vol. 290, p. 471-473.
Cederholm et al., PNAS, 1988, vol. 85, p. 4865-4868.
DeMayo, “Advantages and Pitfalls of Transgenic and Mutant Animals,”American Journal of Kidney Diseases,vol. 33, No. 3, pp. 598-600 (1999).
Hildebrandt et al., “Familial Fibrillary Glomerulopathies: What is the Role of Fibronectin?”Advances in Nephrology,vol. 28, pp. 429-437 (1998).
Kundu, Gopal C., et al., “Recombinant Human Uteroglobin Suppresses Cellular Invasiveness via a Novel Class of High-affinity Cell Surface Binding Site,”Proc. Natl. Acad. Sci. USA,Apr. 1996, pp. 2915-2919, vol. 93.
Kundu, Gopal C., et al., “Uteroglobin (UG) Suppresses Extracellular Matrix Invasion by Normal and Cancer Cells that Express the High Affinity UG-binding Proteins,”The Journal of Biological Chemistry,Aug. 28, 1998, pp. 22819-22824, vol. 273, No. 35.
Laing et al., “A polymorphism of the CC16 gene is associated with an increased risk of asthma,”J. Med. Genet..vol. 35, pp. 463-467 (1998).
Laville et al., Nephrol Dial Transplant, 2004. 19:1947-1951.
Mandal, Asim K., et al. “Uteroglobin Inhibits Prostaglandin F2aReceptor-mediated Expression of Genes Critical for the Production of Pro-inflammatory Lipid Mediators,”The Journal of Biological Chemistry,vol. 280, No. 38, pp. 32897-32904, Sep. 23, 2005.
Mandal, Asim K., et al., “Uteroglobin Represses Allergen-induced Inflammatory Response by Blocking PGD2Receptor-mediated Functions,”The Journal of Experimental Medicine,May 17, 2004, pp. 1317-1330, vol. 199, No. 10.
Mathis, et al., “Isolates ofEncephalitozoon cuniculifrom farmed blue foxes (Alopex lagopus) from Norway differ from isolates from Swiss domestic rabbits (Oryctolagus cuniculus),”Parasitol Res.,vol. 82, pp. 727-730 (1996).
Metzler et al., Nature Struc. Biol. 1997, 4:527-531.
Ngo et al., 1994, Protein Folding Problem and tertiary Structure Prediction, p. 492-295.
Nortier et al., “Proximal tubular injury in Chinese herb nephropathy: monitoring by neutral endopeptidase enzymuria,”Kidney International,vol. 51, No. 1, pp. 288-293 (1997) (Abstract).
Skolnick et al., TIBS, 2000; 18(1):34-39.
Szelestei, et al., “Association of Uteroglobin Polymorphism with Rate of Progression in Patients with IgA Nephropathy,”American Journal of Kidney Diseases,vol. 36, No. 3, pp. 468-473 (2000).
Yumane et al., “Bistable Electro-optical Fast Switching for Induced Smectic (Liquid Crystalline Polymer/Liquid Crystals) and (Pseudo Liquid Crystalline Copolymer/Liquid Crystals) Composite Systems,”Macromolecules,vol. 30, pp. 3234-3241 (1997).
Zheng et al., “Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice,”Nature Medicine,vol. 5, No. 9, pp. 1018-1025 (1999).

Affiliated with

Also associated with

Rating

Uteroglobin in the treatment of IGA mediated nephropathy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Uteroglobin in the treatment of IGA mediated nephropathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uteroglobin in the treatment of IGA mediated nephropathy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4296673